## RESEARCH



# Use of serum albumin levels and salivary biomarkers in assessing periodontal disease: a community hospital perspective



Ping-Chen Chung<sup>1</sup> and Ta-Chien Chan<sup>2,3,4,5\*</sup>

## Abstract

**Background** Periodontal status can be reflected in serum and oral biomarkers. Salivary biomarkers are novel screening tools for individuals with dentophobia or disabilities. This study aimed to explore the differences in SiLL-Ha results and serum albumin levels between clinical attachment loss (CAL)  $\geq$  5 mm (Group A) and CAL < 5 mm (Group B) as well as the influence of sex on these differences.

**Methods** This study recruited healthy adults aged 35–80 years from a community hospital. Participants completed a demographic questionnaire. We collected the participants' medical history, including hypertension, diabetes mellitus (DM) and hyperlipidemia, from electronically stored medical records. Additionally, they underwent a collaborated saliva test, an oral examination including records of clinical attachment levels, and a blood test to measure albumin levels sequentially. Participants were divided into Group A and Group B based on a CAL cut-off point of 5 mm. Multivariable logistic regression was used to analyze associations between the SiLL-Ha results, serum albumin levels, periodontitis, and sex stratification.

**Results** The mean age of the 231 participants was 64.4 years, and 58.4% were women. Older age, low serum albumin levels, and high blood levels of SiLL-Ha were associated with periodontitis. Among the women, age and blood level of SiLL-Ha output were significantly associated with periodontitis. Among men, serum albumin level was significantly associated with periodontitis, particularly females.

**Conclusions** The saliva test is a noninvasive tool applicable not only in dental clinics but also in community settings. It is beneficial for self-monitoring of oral health and promoting health awareness and behavior.

Keywords SiLL-Ha, Salivary test, Periodontitis, Community hospital

\*Correspondence:

## Background

Individuals with dentophobia may avoid dental treatment even when experiencing severe oral pain. A recent metaanalysis estimated the global prevalence of dental fear and anxiety at 15.3% (95% confidence interval [CI]: 10.2, 21.2), with a higher prevalence among women (19.1%) [1]. In Taiwan, the estimated prevalence of dental anxiety was estimated to be 20.6% among 5–8 year-old children [2]. In dental practice, current management strategies for relieving and mitigating dental fear include virtual reality distraction techniques, music therapy, aromatherapy, and cognitive-behavioral therapy [3]. For individuals,



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Ta-Chien Chan

dachianpig@gmail.com

<sup>&</sup>lt;sup>1</sup> Department of Dentistry, Puzi Hospital, Ministry of Health and Welfare, Chiayi, Taiwan

<sup>&</sup>lt;sup>2</sup> Research Center for Humanities and Social Sciences, Academia Sinica,

<sup>128</sup> Academia Road, Section 2, Nankang, Taipei 115, Taiwan

<sup>&</sup>lt;sup>3</sup> Institute of Public Health, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

<sup>&</sup>lt;sup>4</sup> Department of Public Health, College of Public Health, China Medical University, Taichung Campus, Taichung, Taiwan

<sup>&</sup>lt;sup>5</sup> School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan

especially those with dentophobia, serum and salivary biomarkers serve as useful screening tools for target oral diseases, including periodontitis [4, 5]. Traditionally, the stage of periodontitis is diagnosed by assessing clinical attachment loss (CAL) [6]. Serum biomarkers, including C-reactive protein, matrix metalloproteinases [4], interleukins [7], and tumor necrosis factor-alpha [8] are useful for diagnosing and monitoring periodontitis in both treated and untreated patients and for evaluating treatment response. Moreover, serum albumin is a marker of periodontitis, which is associated with inflammation and infection [9]. Inflammation decreases serum albumin levels [10].

Various saliva tests have been developed [4]. SiLL-Ha (https://sillhasaliva.com/), is portable saliva test system using optical detection to assess the risk of periodontal disease and caries, as well as to evaluate oral cleanliness. The SiLL-Ha system is suitable for routine screening and rapid reporting. Users can follow the suggestions provided by the SiLL-Ha results to improve their oral hygiene and seek professional dental advice and treatments. To date, few studies have applied the SiLL-Ha in oral health screening programs. A previous study reported that leukocyte esterase activity, as measured using SiLL-Ha, significantly differed between the baseline and final examinations (9 months after the baseline examination). All 36 participants underwent scaling and root planing, followed by a re-examination 3 months after the baseline. Subsequently, participants received supportive periodontal therapy every 3 months, with the final examination conducted 6 months after the reexamination [11]. In another study, 34 individuals with a > 5 mm pocket depth had higher leukocyte and protein levels, as measured by SiLL-Ha, than 70 individuals with a pocket depth of  $\leq 5 \text{ mm}$  [12].

This study aimed to identify individuals with high risk of periodontitis (CAL  $\geq$  5 mm) in a community hospital setting and to explore the differences in SiLL-Ha results and serum albumin levels between these individuals and those with CAL < 5 mm. The secondary objective was to examine whether these differences were influenced by sex.

## Methods

## **Study participants**

This study was conducted at the Dental Department of Puzi Hospital, Chiayi County, Taiwan between November 01, 2021, and December 31, 2022. Participants were healthy adults aged 35–80 years. Exclusion criteria included a history of pharyngeal and laryngeal surgery, stroke, cerebral palsy, myasthenia gravis, oral cancer, aspiration pneumonia, moderate-to-severe Parkinson's disease, moderate-to-severe dementia, or Alzheimer's disease. Written informed consent was obtained from all participants after they fully understood the study. This study was approved by the Institutional Review Board of Biomedical Science Research, Academia Sinica (AS-IRB-BM-21047).

The sample size was determined by rejecting the null hypothesis using a two-tailed test with an effect size of 0.5, a significance level of 0.05, and a power of 0.95. The suggested sample size was 220 participants. In total, 231 participants were recruited.

Participants were divided into Group A and Group B. The Group A was defined based on the criteria established by the American Academy of Periodontology (AAP) and European Federation of Periodontology (EFP) [13]. Those with at least one site exhibiting a CAL of  $\geq$  5 mm were classified in the Group A [6].

## Data collection

Participants completed a demographic questionnaire (Supplement). Participants completed a demographic questionnaire (Supplement). We collected the participants' medical history, including hypertension, diabetes mellitus (DM), and hyperlipidemia, from electronically stored medical records. Additionally, they underwent a collaborative saliva test, an oral examination including records of clinical attachment levels, and a blood test to measure albumin levels sequentially. Saliva testing was performed using SiLL-Ha (SILL-Ha<sup>®</sup> ST-4910; ARKRAY Inc., Kyoto, Japan) by following the manufacturers' instructions (https://www.arkrayusa.com/sites/ arkrayusa.com/files/SiLL-Ha\_Operating\_Manual.pdf). The participants were instructed not to drink, eat, or brush their teeth for 2 h before testing. Participants were asked to spit their saliva sample into a paper cup after rinsing of mouth with 3 mL of sterile water for 10 s. A droplet of the sample was placed on a test strip and loaded into the instrument for measurement. The analyzer measured cariogenic bacteria, acidity, buffer capacity, blood, leukocyte, protein, and ammonia. The value of each test item ranged from 0 to 100.

Participants underwent blood testing for albumin measurement. Serum albumin levels were analyzed using the Automatic Clinical Chemistry Analyzer TBA-NX360 (Canon, Japan), employing the bromocresol green method with the BioAccut ALB Kit (TUNYEN, Taiwan).

## Statistics analysis

The chi-square test was performed to compare the distribution of sex, hypertension, DM and hyperlipidemia between the Group A and Group B. Fisher's exact tests were used to determine the association between smoking and periodontal status. The Mann–Whitney U test was used to compare the differences in age, saliva test results,

and serum albumin levels between the Group A and Group B for non-normally distributed data, after conducting the Shapiro-Wilk normality test. The distribution of periodontal parameters, including the mean CAL and number of sites with deep CAL of 5 mm or more, was calculated. We conducted the Spearman correlation test to explore the correlation between the number of sites with deep CAL of 5 mm or more and biochemical parameters, including serum albumin levels and SiLL-Ha results. Multivariable logistic regression models were used to analyze the associations between the SiLL-Ha results, serum albumin levels, periodontal status, and stratification by sex. Since all female participants were non-smokers, smoking habits were not included in the logistic regression with sex stratification. The area under the receiver operating characteristic curve (AUC) and receiver operating characteristic (ROC) curve were used to evaluate the predictive performance of salivary and serum biomarkers. Additionally, a combined approach using logistic regression was applied after adjusting for age, sex, and medical history of hypertension, DM, and hyperlipidemia. Statistical significance was set at p < 0.05. The R software (version 4.3.1) [14] was used for all data management and statistical analyses.

## Results

This study included 231 participants with a mean age of 64.4 years (standard error [SE] = 0.74), of whom 135 participants were female, accounting for 58.4%. Participants with hypertension, DM, and hyperlipidemia accounted for 14.3%, 25.5%, and 32.9%, respectively. Nonsmokers accounted for 88.3% of the total population. SiLL-Ha outputs yielded the following results: mean score of cariogenic bacteria, 16.9 (SE=1.32); acidity, 64.8 (SE=1.50); buffer capacity, 11.2 (SE=0.88); ammonia, 21.2 (SE=1.24); blood, 36.4 (SE=1.71); leukocytes, 58.6 (SE=2.03), and protein, 32.4 (SE=1.26). The mean serum albumin level was 4.2 g/dL (SE=0.01). The normal range for adults younger than 60 years is 3.5–5.2 g/dL and for adults aged 60 years and older is 3.2–4.6 g/dL (Table 1).

 Table 1
 Differences in salivary screening results according to the clinical attachment level

	Total ( <i>n</i> = 231)	Group B CAL < 5 mm ( <i>n</i> = 103)	Group A CAL≥5 mm ( <i>n</i> =128)	<i>P</i> value
Age	64.4 (0.74)	61.1 (1.28)	67.2 (0.77)	< 0.001
Sex				0.69
Female	135 (58.4%)	62 (60.2%)	73 (57.0%)	
Male	96 (41.6%)	41 (39.8%)	55 (43.0%)	
Hypertension				0.85
No	198 (85.7%)	89 (86.4%)	109 (85.2%)	
Yes	33 (14.3%)	14 (13.6%)	19 (14.8%)	
DM				0.049
No	172 (74.5%)	70 (68.0%)	102 (79.7%)	
Yes	59 (25.5%)	33 (32.0%)	26 (20.3%)	
Hyperlipidemia				0.67
No	155 (67.1%)	71 (68.9%)	84 (65.6%)	
Yes	76 (32.9%)	32 (31.1%)	44 (34.4%)	
Smoking				0.6
No	204 (88.3%)	90 (87.4%)	114 (89.1%)	
Yes	10 (4.3%)	6 (5.8%)	4 (3.1%)	
Ever, but quit	17 (7.4%)	7 (6.8%)	10 (7.8%)	
Cariogenic bacteria: n (SE)	16.9 (1.32)	16.5 (1.75)	17.3 (1.93)	0.84
Acidity: n (SE)	64.8 (1.50)	65.0 (2.28)	64.7 (1.99)	0.79
Buffer capacity: n (SE)	11.2 (0.88)	11.2 (1.20)	11.2 (1.26)	0.97
Ammonia: n (SE)	21.2 (1.24)	18.9 (1.60)	23.1 (1.81)	0.15
Blood: n (SE)	36.4 (1.71)	32.7 (2.50)	39.5 (2.32)	0.04
Leukocyte: n (SE)	58.6 (2.03)	56.4 (3.04)	60.3 (2.73)	0.25
Protein: n (SE)	32.4 (1.26)	31.1 (1.88)	33.5 (1.71)	0.28
Albumin: n (SE)	4.2 (0.01)	4.29 (0.02)	4.19 (0.02)	< 0.001

Abbreviation: CAL Clinical attachment level, SE Standard error

The mean CAL was 1.94 (SE = 2.08) and number of sites with deep CAL of 5 mm or more was 5.17 (SE = 0.54).

In total, 128 participants were classified as Group A and 103 participants were classified as the Group B. Age, DM, blood level of SiLL-Ha, and serum albumin levels were significantly different between the Group A and Group B. In the Group A, the mean age was higher (mean = 67.2, SE = 0.77), blood levels of SiLL-Ha were higher (mean = 39.5, SE = 2.32), and serum albumin levels were lower (mean=4.19, SE=0.02) than those in the Group B (Table 1). However, a higher percentage of participants in the Group B (32.0%) than in the Group A (20.3%) had DM. Serum albumin, as well as blood and ammonia levels from the SiLL-Ha results, were significantly correlated with CAL. Participants with older age, low serum albumin, and high blood levels of SiLL-Ha were more likely to develop periodontitis. Among women, older adults (coefficient=0.07; 95% CI: 0.03, 0.12) and participants with high blood level of SiLL-Ha output (coefficient=0.03; 95% CI: 0.01, 0.05) had higher risk to have periodontitis. Among men, low serum albumin level (coefficient = -5.02; 95% CI: -8.25, -2.21) were associated with a higher probability of periodontitis (Table 2). Participants with DM were less likely to have periodontitis, particularly females.

The AUC values, which indicate predictive performance, for salivary biomarkers, serum biomarkers, and the combined approach were 0.72, 0.70, and 0.73, respectively. The ROC curves, for salivary biomarkers, serum biomarkers, and the combined approach were presented in Fig. 1A, B, and C.

## Discussion

Older age, no DM diagnosis, high blood SiLL-Ha levels, and lower albumin levels were associated with periodontitis. Sex differences were observed in the relationship between serum albumin, blood levels of SiLL-Ha, and periodontitis. Aging is a time-dependent impairment of biomechanisms, including changes in the immune response [15]. Aging induces dysregulation of the immune response, which increases the susceptibility to inflammatory response [16]. Middle-aged and older adults have a high prevalence of periodontal disease and gingival bleeding, and deep periodontal pockets [17].

Free hemoglobin levels differ significantly between individuals with severe periodontitis and those without periodontal disease [18]. Free hemoglobin concentration was higher in the severe periodontitis group than in the no periodontal disease group. Severe periodontitis was classified as having at least one probing depth of 6 mm or more [18]. Moreover, a deeper periodontal pocket depth is associated with a significantly higher incidence of bleeding on probing, indicating inflammation of the periodontal tissue [19]. Bleeding is a sentinel sign of periodontitis risk. Self-reported gingival bleeding during brushing [20] and self-reported bleeding gums [21] help predict periodontitis and distinguish periodontal health and disease.

In this study, women in the Group A had significantly higher blood levels from SiLL-Ha scores than women in the Group B. Changes in hormone levels due to menopause may contribute to this finding [22]. Estrogen deficiency negatively affects the immune response. In the postmenopausal stage, levels of pro-inflammatory cytokines increase and immune responses to pathogens decrease, causing high susceptibility to infection [22]. Cytokines such as interleukin (IL)-6 promote active bone resorption and periodontal inflammation [22, 23].

An inverse relationship exists between serum albumin levels and the severity of chronic periodontitis [24]. Decreased serum albumin levels have also been reported in patients with aggressive periodontitis [25]. In one study, the chronic periodontitis group showed a decline in serum albumin levels after 3 months of non-surgical periodontal treatment compared with the healthy periodontal group [24]. Microorganisms cause destruction of the periodontal tissue and lead to change of inflammatory cytokines concentration such as IL-1 $\beta$ , IL-6, and tumor necrosis factor-alpha [24]. However, serum albumin concentration is also influenced by nutritional status, especially in older adults with impaired dentition and systemic diseases. Albumin is a useful index of periodontal inflammation, but the explanation should be concluded carefully [26]. There was no clear explanation for the significant association between serum albumin levels and periodontitis observed only in men. Sex disparities in biology, microbial etiology, socioeconomic status, lifestyle, and behavior may play a role in periodontal disease [27].

DM exacerbates susceptibility to periodontitis by impairing the immune response, inducing both local and systemic inflammatory responses, decreasing collagen turnover, and altering the subgingival microbial profile [28, 29]. In our study, participants were recruited from a single hospital. The proportion of participants with DM was lower in the Group A than in the Group B, which is different from the results of nationwide, large population-based retrospective cohort studies [30-32]. Studies using the Taiwan National Health Insurance Research Database show a higher prevalence of DM among patients with periodontitis than among those without periodontitis. Contrary to previous study findings, our results showed that individuals without a DM diagnosis had a higher risk of periodontitis [28, 29], which may be attributed to the small sample size of our study.

Acefficient 55% C         Poulle         Coefficient 55% C         Poulle         Coefficient 55% C         Poulle           Age         05(002,000)         0002**         007003,012)         0003**         001(-004,006)         0.012           Age         05(002,003)         0002**         007003,012)         0003**         001(-004,006)         0.72           Sex         05(-02,034)         046         0.7003,012)         0.003**         0.01(-004,006)         0.72           Sex         036(-128,134)         0.46         0.76         0.016(-04,006)         0.72           Sex but up         036(-128,134)         0.47         0.47         1.46         1.66           Sex but up         0.36(-13,134)         0.79         0.016(-136,123)         0.73           No         Ref         0.77         0.77         1.46,116         0.79           Sex but up         0.46(-0.23,124)         0.47         0.76         0.10(-136,123)         0.88           No         Ref         0.77         0.77         0.79         0.10(-136,123)         0.16           No         Ref         0.77         0.77         0.79         0.16(-136,123)         0.16           No         Ref         0.77 <th></th> <th>Total</th> <th></th> <th>Female</th> <th></th> <th>Male</th> <th></th>		Total		Female		Male	
Age         0.03(n0.10.09)         0.002**         0.07(n0.5, 0.1.2)         0.003**         0.01(n0.6, 0.06)         0.22           Fermile         Rf         0.03(n0.10.09)         0.02**         0.03(n0.5, 0.1.2)         0.03           See         Termile         Rf         0.02*(n.3, 0.90)         0.02*         0.03(n1.5, 0.1.5)         0.02           Servicing         Add         0.04'         0.04'         0.04'         0.01'(146, 116)         0.03         0.01'(136, 121)         0.03           Servicing         Def         0.07'         Def         0.07'         Def         0.01'(146, 116)         0.03         0.03         0.03           No         Ref         0.07'         Def         0.07'(146, 116)         0.03'         0.01'(136, 121)         0.08           No         Ref         0.07'(146, 116)         0.02'         0.11'(146, 116)         0.03'         0.01'(136, 121)         0.08           No         Ref         0.07'(146, 116)         0.02'         0.11'(146, 116)         0.02'         0.01'(136, 123)         0.08           No         Ref         0.07'(146, 116)         0.02'         0.11'(142, 11', 0.1')         0.02'         0.01'(12, 0.1')         0.08         0.01'(12, 0.1')         0.08' <th></th> <th>Coefficient 95% Cl</th> <th>Pvalue</th> <th>Coefficient 95% CI</th> <th>P value</th> <th>Coefficient 95% Cl</th> <th>P value</th>		Coefficient 95% Cl	Pvalue	Coefficient 95% CI	P value	Coefficient 95% Cl	P value
Set         Set           Fenale         Ref           Fenale         Ref           Sroling         0.26(4.2.0.9)           Sroling         0.26(4.2.0.9)           Sroling         Ref           Sroling         0.36(4.2.0.9)           Sroling         0.36(4.2.0.9)           No         Ref           Visi         0.36(4.2.0.9)           Stroling         0.30(4.2.0.9)           No         Ref           N	Age	0.05(0.02,0.09)	0.002**	0.07(0.03, 0.12)	0.003**	0.01(-0.04, 0.06)	0.72
Female         Ref           Male         0.36(-0.32, 0.34)         0.46           Snoking         Ref         0.36(-0.32, 0.34)         0.46           No         Ref         0.36(-0.32, 0.34)         0.46           No         Ref         0.36(-0.32, 0.34)         0.46           Yes         0.30(-1.38, 1.34)         0.37         0.37           Hypertension         Ref         0.47         0.47           No         Ref         0.37         0.17(-1.44, 1.16)         0.79           No         Ref         0.37         0.17(-1.44, 1.16)         0.89           No         Ref         0.37         0.31(-1.34, 0.40)         0.86           No         Ref         0.37(-1.34, 0.40)         0.33         0.31           No         Ref         0.31(-1.34, 0.40)         0.37         0.36           No         Ref         0.31(-1.36, 1.21)         0.36         0.36           No         Ref         0.31(-1.36, 1.21)         0.36         0.36           No         Ref         0.31(-1.36, 1.21)         0.36         0.36           No         Ref         0.32(-0.31, 0.30)         0.37         0.36           No         R	Sex						
Male         0.26(-0.42, 0.94)         0.66           Smoking         5           Smoking         6           Yes         0.30(-1.28, 1.84)         0.70           Yes         0.30(-1.28, 1.84)         0.70           Hypertension         6         0.75           Mo         Ref         0.77           No         Ref         0.77           Mo         6         0.75           Mo         6         0.75           Mo         8         0.75           No         8         0.75           Mo         8         0.75           Mo         8         0.74(-0.2)           Mo         8         0.74(-0.2) <t< td=""><td>Female</td><td>Ref</td><td></td><td></td><td></td><td></td><td></td></t<>	Female	Ref					
Smoking         Smoking           No         Ref           Vers         0.30(-1.2k, 1.84)         0.70           Vers         0.30(-1.2k, 1.84)         0.70           Hypernersion         Ref         0.30(-1.2k, 1.84)         0.70           Vers         0.27(-1.13, 0.60)         0.54         -0.17(-1.46, 1.16)         0.79         0.10(-1.36, 1.21)         0.88           Vers         -0.27(-1.13, 0.60)         0.54         -0.17(-1.46, 1.16)         0.79         -0.10(-1.36, 1.21)         0.88           Vers         -0.27(-1.13, 0.60)         0.54         -0.17(-1.46, 1.16)         0.79         -0.10(-1.36, 1.21)         0.88           No         Ref          -0.27(-1.12, 0.40)         0.79         -0.10(-1.36, 1.21)         0.88           Vers         -1.11(-1.84, -0.40)         0.74         -0.74(-0.32, 1.20)         0.16         0.01           No         Ref          -1.14(-2.17, -0.17)         0.22         -0.36(-1.97, 0.32)         0.16           No         Ref          -0.12(-0.12, 0.20)         0.21         0.36(-1.97, 0.32)         0.16           No         Ref           -0.13(-2.43, 2.20)         0.21         0.01(-0.02, 0.03)	Male	0.26(-0.42, 0.94)	0.46				
No         Ref           Ves         0.30(-1.38, 1.34)         0.70           Fver.burgut         0.46(-0.38, 1.34)         0.71           Fver.burgut         0.46(-0.38, 1.34)         0.47           Hypertension         8           No         Fef	Smoking						
Ves         0.30(-1.3k, 1.94)         0.70           Feve. bur quit         0.46(-0.3k, 1.74)         0.47           Hypernesion         86         0.27(-113.060)         0.47           Ves         -0.27(-113.060)         0.24         -0.17(-1.46, 1.16)         0.79           Ves         -0.27(-113.060)         0.24         -0.17(-1.46, 1.16)         0.29           No         Ref         -0.27(-113.060)         0.24         -0.17(-1.46, 1.16)         0.38           No         Ref         -0.27(-113.060)         0.24         -0.17(-1.46, 1.16)         0.39           No         Ref         -0.27(-1.13.060)         0.24         -0.17(-1.46, 1.16)         0.38           No         Ref         -1.11(-1.34, -0.40)         0.02*         -1.14(-2.17, -0.17)         0.38           No         Ref         -1.11(-1.34, -0.40)         0.02*         -0.30(-1.32)         0.16           No         Ref         -1.14(-2.17, -0.17)         0.02*         -0.30(-1.35, 1.21)         0.38           No         Ref         -1.11(-1.34, -0.40)         0.02*         0.30(-1.32, 0.22)         0.16           No         Ref         -1.11(-2.13, -0.17)         0.02*         0.30(-1.32, 0.2)         0.16	No	Ref					
Feer but atti         046(-0.78, 1.74)         047           Hypertension	Yes	0.30(-1.28, 1.84)	0.70				
Hypertension         No         Ref         0.01(-136, 1.21)         0.08           No         Ref         0.027(-113,0.60)         0.54         -0.17(-1.46, 1.16)         0.79         -0.10(-1.36, 1.21)         0.88           No         Ref         0.027(-113,0.60)         0.54         -0.17(-1.46, 1.16)         0.79         -0.10(-1.36, 1.21)         0.88           No         Ref         0.003**         -1.14(-2.17, -0.17)         0.02*         -0.06(-1.97, 0.32)         0.16           Ves         0.111(-1.34, -0.40)         0.003**         -1.14(-2.17, -0.17)         0.02*         -0.01(-0.5, 0.02)         0.16           Ves         0.44(-0.22, 1.12)         0.003*         -1.14(-2.17, -0.17)         0.02*         -0.06(-1.97, 0.32)         0.16           No         Ref         0.00         0.01         0.02         0.01(-0.66, 1.09)         0.02*         0.016           Ves         0.44(-0.22, 1.12)         0.02         0.02         0.01(-0.60, 0.02)         0.02         0.016         0.016           No         Ref         0.001         0.02         0.02         0.016         0.016         0.016         0.016         0.016         0.016           Active         0.002(-0.01, 0.02)         0.22 <t< td=""><td>Ever, but quit</td><td>0.46(-0.78, 1.74)</td><td>0.47</td><td></td><td></td><td></td><td></td></t<>	Ever, but quit	0.46(-0.78, 1.74)	0.47				
No         Ref         0.79         0.10(-136, 1.21)         0.88           Yes         -0.27(-113,0.60)         0.54         -0.17(-146, 1.16)         0.79         0.010(-136, 1.21)         0.88           DM         Ref         -         -         -         -         0.00(-136, 1.21)         0.88           Ves         1.11(-1.34, -0.40)         0.03**         -1.14(-2.17, -0.17)         0.02*         -0.16(-137, 0.32)         0.16           Ves         -         -         -         -         -         -         0.16           Ves         -         -         -         -         -         0.02*         0.16           Ves         0.44(-0.22, 1/2)         0.20         0.21(-0.66, 1/09)         0.64         0.74(-0.39, 1/96)         0.16           Ves         0.44(-0.22, 1/12)         0.20         0.21(-0.66, 1/09)         0.64         0.74(-0.39, 1/96)         0.16           Albumin         -1.95(-3.67, -0.29)         0.02         0.01(-0.01, 0.02)         0.02         0.01(-0.01, 0.03)         0.01           Albumin         -1.95(-3.67, -0.29)         0.02         0.01(-0.02, 0.02)         0.01(-0.02, 0.02)         0.01         0.01           Albumin         -1.95(-3.67, -0.29)	Hypertension						
Yes         -0.27(-1.13, 0.60)         0.54         -0.17(-1.46, 1.16)         0.79         -0.10(-1.36, 1.21)         0.88           DM         Ref               0.03           No         Ref               0.06(-136, 1.21)         0.08           Ves         -1.11(-1.184, -0.40)         0.003**         -1.14(-2.17, -0.17)         0.02*         -0.80(-197, 0.32)         0.16           Ves         -1.11(-1.184, -0.40)         0.003**         -1.14(-2.17, -0.17)         0.02*         -0.80(-197, 0.32)         0.16           Hyperlipidemia               0.01           No         Ref              0.01          0.016         0.016         0.016         0.016          0.016          0.016         0.016         0.016         0.016         0.016         0.016         0.016          0.016         0.016         0.016         0.016         0.016         0.016         0.016         0.016         0.016         0.016         0.016         0.016         <	No	Ref					
DM         No         Ref         0.003**         -1.14(-2.17, -0.17)         0.02*         -0.80(-1.97, 0.32)         0.16           Yes         -1.11(-1.34, -0.40)         0.003**         -1.14(-2.17, -0.17)         0.02*         -0.80(-1.97, 0.32)         0.16           Hyperlipidemia         No         Ref         -1.11(-1.34, -0.40)         0.003**         -1.14(-2.17, -0.17)         0.02*         -0.80(-1.97, 0.32)         0.16           No         Ref         0.44(-0.22, 1.12)         0.20         0.01(-0.02, 0.03)         0.21         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.03         0.01         0.03         0.01         0.03         0.01         0.03         0.01         0.03         0.03         0.01         0.03	Yes	-0.27(-1.13, 0.60)	0.54	-0.17(-1.46, 1.16)	0.79	-0.10(-1.36, 1.21)	0.88
No         Ref	DM						
Yes         -1.11(-1.84, -0.40)         0.003**         -1.14(-2.17, -0.17)         0.02*         -0.80(-1.97, 0.32)         0.16           Hyperlipdemia         No         Ref              0.02*         -1.14(-2.17, -0.17)         0.02*         0.01(-0.02, 0.13)         0.01           No         Ref              0.04(-0.22, 1.12)         0.02         0.01(-0.05, 0.03)         0.01         0.01(-0.02, 0.03)         0.01           Albumin         -1.95(-3.67, -0.29)         0.02*         -0.13(-2.43, 2.20)         0.91         -5.502(-8.25, -2.21)         0.01(+	No	Ref					
Hyperligidemia         No         Ref         0.44(-0.22, 1.12)         0.20         0.21(-0.66, 1.09)         0.64         0.74(-0.39, 1.96)         0.21           Ne         0.44(-0.22, 1.12)         0.20         0.21(-0.66, 1.09)         0.64         0.74(-0.39, 1.96)         0.21           Albumin         -1.95(-357, -0.29)         0.02*         -0.13(-2.43, 2.20)         0.91         -5.02(-8.25, -2.21)         0.001**           Albumin         -1.95(-0.01) 0.02)         0.55         0.003(-0.02, 0.03)         0.82         0.01(-0.02, 0.03)         0.63           Acidity         -0.01(-0.03, 0.01)         0.24         -0.01(-0.03, 0.02)         0.82         0.01(-0.02, 0.03)         0.63           Buffer capacity         -0.01(-0.03, 0.01)         0.24         -0.01(-0.03, 0.02)         0.63         0.02           Armonia         0.01(-0.01, 0.03)         0.27         0.03(-0.01, 0.04)         0.21         -0.001(-0.05, 0.05)         0.73           Blood         0.02(-001, 0.03)         0.24         0.01(-0.05, 0.02)         0.24         0.001(-0.05, 0.02)         0.73           Blood         0.01(-0.01, 0.03)         0.24         0.01(-0.05, 0.02)         0.24         0.001(-0.05, 0.02)         0.73           Leukocyte         0.01(-0.01, 0.01)         <	Yes	-1.11(-1.84, -0.40)	0.003**	-1.14(-2.17, -0.17)	0.02*	-0.80(-1.97, 0.32)	0.16
No         Ref           Yes         0.44(-0.22, 1.12)         0.20         0.21(-0.66, 1.09)         0.64         0.74(-0.39, 1.96)         0.21           Albumin         -1.95(-3.67, -0.29)         0.02*         -0.13(-2.43, 2.20)         0.91         -5.02(-8.25, -2.21)         0.001**           Albumin         -1.95(-3.67, -0.29)         0.02*         -0.13(-0.23, 0.03)         0.031         0.001         -5.02(-8.25, -2.21)         0.001**           Cariogenic         0.005(-001, 0.02)         0.55         0.003(-0.02, 0.03)         0.23         0.01(-0.02, 0.03)         0.63           Acidity         -0.01(-0.03, 0.01)         0.24         -0.01(-0.03, 0.02)         0.63         0.63           Acidity         -0.01(-0.01, 0.03)         0.29         -0.01(-0.03, 0.02)         0.53         0.01(-0.05, 0.05)         0.63           Buffer capacity         -0.02(-0.05, 0.01)         0.24         0.03(-0.01, 0.03)         0.63         0.62           Anmonia         0.01(-0.01, 0.03)         0.27         0.03(-0.01, 0.03)         0.24         0.001(-0.05, 0.02)         0.79           Blood         0.02(-001, 0.03)         0.03         0.21         0.02         0.003(-0.02, 0.03)         0.79           Icuokocytre         0.01(-0.01, 0.01)	Hyperlipidemia						
Yes0.44(-0.22, 1.12)0.200.21(-0.66, 1.09)0.640.74(-0.39, 1.96)0.21Albumin-1.95(-3.67, -0.29)0.02*-0.13(-2.43, 2.20)0.91-5.02(-8.25, -2.21)0.001**Albumin-1.95(-3.67, -0.29)0.0550.003(-0.02, 0.03)0.820.01(-0.02, 0.03)0.63Cariogenic0.005(-0.01, 0.02)0.550.003(-0.02, 0.03)0.820.01(-0.02, 0.03)0.63Acidity-0.01(-0.03, 0.01)0.24-0.01(-0.03, 0.02)0.53-0.01(-0.03, 0.02)0.63Memoria0.01(-0.01, 0.03)0.20-0.03(-0.07, 0.02)0.24-0.001(-0.05, 0.05)0.95Memoria0.01(-0.01, 0.03)0.270.02(-0.01, 0.04)0.24-0.001(-0.05, 0.05)0.95Memoria0.01(-0.01, 0.03)0.270.02(-0.01, 0.04)0.21-0.005(-0.04, 0.03)0.79Blood0.02(0.001, 0.03)0.840.001(-0.02, 0.02)0.95-0.002(-0.02, 0.02)0.79Leukocyte0.01(-0.01, 0.01)0.840.001(-0.02, 0.02)0.95-0.002(-0.02, 0.02)0.79Leukocyte0.01(-0.01, 0.01)0.48-0.01(-0.02, 0.02)0.95-0.002(-0.02, 0.02)0.79Leukocyte0.01(-0.01, 0.01)0.48-0.01(-0.02, 0.02)0.95-0.002(-0.02, 0.02)0.79Leukocyte0.01(-0.01, 0.01)0.48-0.01(-0.02, 0.02)0.95-0.002(-0.02, 0.02)0.79Leukocyte0.01(-0.01, 0.01)0.48-0.01(-0.02, 0.02)0.95-0.002(-0.02, 0.02)0.79	No	Ref					
Albumin         -1.95(-367, -0.29)         0.02*         -0.13(-2.43, 2.20)         0.91         -5.02(-8.25, -2.21)         0.001**           Cariogenic         0.005(-0.01, 0.02)         0.55         0.003(-0.02, 0.03)         0.82         0.01(-0.02, 0.03)         0.63           Dacteria         0.001(-0.03, 0.01)         0.24         -0.01(-0.03, 0.02)         0.63         0.63           Acidity         -0.01(-0.03, 0.01)         0.24         -0.01(-0.05, 0.05)         0.63         0.63           Acidity         -0.01(-0.01, 0.03)         0.20         0.02(-001, 0.04)         0.24         -0.001(-0.05, 0.05)         0.95           Armonia         0.01(-0.01, 0.03)         0.27         0.02(-001, 0.03)         0.21         -0.001(-0.05, 0.02)         0.78           Blood         0.02(001, 0.03)         0.24         0.01(-0.01, 0.03)         0.24         0.001(-0.02, 0.02)         0.78           Leukocyte         0.001(-0.01, 0.01)         0.84         0.001(-0.02, 0.02)         0.92         0.002(-0.02, 0.02)         0.78           Leukocyte         0.001(-0.01, 0.01)         0.84         0.001(-0.02, 0.02)         0.95         0.002         0.79         0.79           Leukocyte         0.001(-0.01, 0.01)         0.49         0.022         0.002	Yes	0.44(-0.22, 1.12)	0.20	0.21(-0.66, 1.09)	0.64	0.74(-0.39, 1.96)	0.21
Cariogenic0.005(-0.01, 0.02)0.550.003(-0.02, 0.03)0.620.01(-0.02, 0.03)0.63bacteria-0.01(-0.03, 0.01)0.24-0.01(-0.03, 0.02)0.53-0.01(-0.03, 0.02)0.63Acidity-0.01(-0.03, 0.01)0.20-0.03(-0.07, 0.02)0.24-0.001(-0.05, 0.05)0.95Buffer capacity-0.01(-0.01, 0.03)0.270.02(-0.01, 0.03)0.270.270.79Blood0.02(0.001, 0.03)0.04*0.03(0.01, 0.05)0.02*-0.003(-0.03, 0.02)0.79Leukocyte0.001(-0.01, 0.01)0.840.001(-0.02, 0.02)0.95-0.002(-0.02, 0.02)0.79Votein-0.01(-0.01, 0.01)0.48-0.01(-0.02, 0.02)0.95-0.002(-0.02, 0.02)0.79Protein-0.01(-0.03, 0.01)0.48-0.01(-0.05, 0.02)0.95-0.002(-0.02, 0.02)0.79	Albumin	-1.95(-3.67, -0.29)	0.02*	-0.13(-2.43, 2.20)	0.91	-5.02(-8.25, -2.21)	0.001 **
Acidity-0.01(-0.03, 0.01)0.24-0.01(-0.03, 0.02)0.63Buffer capacity-0.02(-0.05, 0.01)0.20-0.03(-0.07, 0.02)0.24-0.001(-0.05, 0.05)0.95Ammonia0.01(-0.01, 0.03)0.270.02(-0.01, 0.04)0.21-0.005(-0.04, 0.03)0.78Blood0.02(0.001, 0.03)0.04*0.03(001, 0.05)0.02*-0.003(-0.03, 0.02)0.79Leukocyte0.001(-0.01, 0.01)0.840.001(-0.02, 0.02)0.95-0.002(-0.02, 0.02)0.79Votein-0.01(-0.01, 0.01)0.48-0.01(-0.02, 0.02)0.95-0.002(-0.02, 0.02)0.83Protein-0.01(-0.03, 0.01)0.48-0.01(-0.05, 0.02)0.95-0.002(-0.02, 0.02)0.83	Cariogenic bacteria	0.005(-0.01, 0.02)	0.55	0.003(-0.02, 0.03)	0.82	0.01(-0.02, 0.03)	0.63
Buffer capacity         -0.02(-0.05, 0.01)         0.20         -0.03(-0.07, 0.02)         0.24         -0.001(-0.05, 0.05)         0.95           Ammonia         0.01(-0.01, 0.03)         0.27         0.02(-0.01, 0.04)         0.21         -0.005(-0.04, 0.03)         0.78           Blood         0.02(0.001, 0.03)         0.04*         0.03(0.01, 0.05)         0.02*         -0.003(-0.02, 0.02)         0.79           Leukocyte         0.001(-0.01, 0.01)         0.84         0.001(-0.02, 0.02)         0.95         -0.002(-0.02, 0.02)         0.83           Protein         -0.01(-0.03, 0.01)         0.49         0.002(-0.02, 0.02)         0.83         0.92	Acidity	-0.01 (-0.03, 0.01)	0.24	-0.01 (-0.03, 0.02)	0.53	-0.01(-0.03, 0.02)	0.63
Ammonia         0.01(-0.01, 0.03)         0.27         0.02(-0.01, 0.04)         0.21         -0.005(-0.04, 0.03)         0.78           Blood         0.02(0001, 0.03)         0.04*         0.03(001, 0.05)         0.04*         0.033(-0.02, 0.02)         0.79           Leukocyte         0.001(-0.01, 0.01)         0.84         0.001(-0.02, 0.02)         0.95         -0.002(-0.02, 0.02)         0.83           Protein         -0.01(-0.01, 0.01)         0.48         -0.01(-0.02, 0.02)         0.83         0.92	Buffer capacity	-0.02(-0.05, 0.01)	0.20	-0.03(-0.07, 0.02)	0.24	-0.001 (-0.05, 0.05)	0.95
Bload         0.02(0.001, 0.03)         0.04*         0.03(0.01, 0.05)         0.02*         -0.003(-0.03, 0.02)         0.79           Leukocyte         0.001(-0.01, 0.01)         0.84         0.001(-0.02, 0.02)         0.95         -0.002(-0.02, 0.02)         0.83           Protein         -0.01(-0.03, 0.01)         0.48         -0.01(-0.05, 0.02)         0.49         0.002(-0.03, 0.04)         0.92	Ammonia	0.01(-0.01, 0.03)	0.27	0.02(-0.01, 0.04)	0.21	-0.005(-0.04, 0.03)	0.78
Leukocyte         0.001(-0.01, 0.01)         0.84         0.001(-0.02, 0.02)         0.95         -0.002(-0.02, 0.02)         0.83           Protein         -0.01(-0.03, 0.01)         0.48         -0.01(-0.05, 0.02)         0.49         0.002(-0.03, 0.04)         0.92	Blood	0.02(0.001, 0.03)	0.04*	0.03(0.01, 0.05)	0.02*	-0.003(-0.03, 0.02)	0.79
Protein         -0.01(-0.03, 0.01)         0.48         -0.01(-0.05, 0.02)         0.49         0.002(-0.03, 0.04)         0.92	Leukocyte	0.001 (-0.01 , 0.01)	0.84	0.001 (-0.02, 0.02)	0.95	-0.002(-0.02, 0.02)	0.83
	Protein	-0.01 (-0.03, 0.01)	0.48	-0.01 (-0.05, 0.02)	0.49	0.002(-0.03, 0.04)	0.92

(2025) 25:679



Fig. 1 The ROC curves for salivary biomarkers, serum biomarkers, and the combined approach. A The ROC curves for salivary biomarkers. B The ROC curves for serum biomarkers. C The ROC curves for the combined approach

SiLL-Ha, a monitoring tool for oral health risk assessment, uses a relatively quick and easy method to collect saliva. The multiparameter salivary test was performed using wavelength reflectance measurements in a short time. This test allows users to routinely self-monitor their oral health and aids in identifying oral conditions, such as dental caries, periodontal disease, and oral malodor. A study involving 36 participants using SiLL-Ha showed a significant difference in leukocyte esterase activity between the baseline and final examinations (9 months after baseline), however, no significant differences were observed in protein and ammonia levels. During the period between the baseline and final examinations, participants received one periodontal treatment and two supportive periodontal therapies [11]. A cross-sectional study involving 104 participants using Sill-Ha reported a significant difference in protein and leukocyte levels between groups with probing depths  $\geq$  5 mm and < 5 mm [12]. Higher protein and leukocyte levels were associated with deeper probing depths. Additionally, blood levels were elevated in the  $\geq$  5 mm group compared to the < 5 mm group (P = 0.058). In our study, we combined saliva and serum biomarkers to screen for potential periodontal disorders, investigate sex differences in biomarker levels, and assess oral health awareness. Our findings indicated that both Sill-Ha blood values and serum albumin levels were significantly associated with periodontal status. Specifically, Sill-Ha blood values showed a stronger association with periodontal status among females, while serum albumin levels were more strongly associated among males. The AUC of study from Deng et al. proposed active matrix metalloproteinase-8 for discriminating periodontal health was superior to that in our study (AUC=0.883) [33]. The subgingival microbial dysbiosis index, computed at the species and genus levels, was used for the integrated data analysis. The results showed the accuracy of periodontitis diagnosis based on the subgingival microbial dysbiosis index for subgingival biofilm, saliva, and tongue had AUC values ranging 0.76-0.90 [34].

This study had several limitations. First, this was a cross-sectional study based on a community dataset; therefore, it did not provide evidence of a temporal relationship and causal inference was not possible. Potential selection bias may limit the extrapolation of our findings to the whole population. Therefore, future studies should recruit participants from diverse community settings and include a longitudinal followup of participants. Moreover, potential confounding factors—such as health behaviors, routine dental examinations, gingival health indicators (e.g., bleeding on probing and probing depth), oral hygiene maintenance, recent periodontal treatment (within the past six months), antibiotic use within the last three months, and pregnancy or lactation status—should be considered in future studies. The incorporation of more comprehensive data enhanced the predictive performance of the model.

## Conclusion

The saliva test is a noninvasive and rapid screening tool that can monitor oral status in a timely manner and has the advantage of easy sample collection. Its applicability extends to community settings, making it particularly beneficial for regular self-monitoring of people with disabilities, difficulty moving, and dentophobia. By providing accessible insights into oral status, the test empowers individuals to monitor their oral health regularly and seek timely dental care based on the results.

#### Abbreviations

- CI Confidence interval
- CAL Clinical attachment loss
- DM Diabetes mellitus
- AUC Area under the receiver operating characteristic curve
- SE Standard error
- IL Interleukin
- ROC Receiver operating characteristic curve

## **Supplementary Information**

The online version contains supplementary material available at https://doi. org/10.1186/s12903-025-06042-x.

Supplementary Material 1.

#### Acknowledgements

We are grateful to Miss Yu-Ping Wang and Mr. Chun-Wei Su for study materials and equipment preparation.

#### Authors' contributions

PCC contributed to conception, design, data collection, data analysis, interpretation and drafted the manuscript. TCC contributed to conception, design, and interpretation, acquired to research resources, and critically revised the manuscript. All the authors have read and approved the final manuscript.

#### Funding

Open access funding provided by Academia Sinica This research was supported by a grant from Academia Sinica, Taiwan (grant number AS-HLGC-110–01) and the article processing fee was supported by the National Science and Technology Council, Taiwan (NSTC 113-2327-B-018-001). The funder had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation.

#### Data availability

The datasets generated and analyzed during the current study are not publicly available due to the informed consent, which specifies that any secondary use must be reviewed and approved by the Institutional Review Board (IRB)

of Academia Sinica. However, the data are available from the corresponding author upon reasonable request.

#### Declarations

#### Ethics approval and consent to participate

The study was approved by the Institutional Review Board (of Biomedical Science Research, Academia Sinica (AS-IRB-BM-21047). Written informed consent was obtained from all participants. This study was performed in accordance with the Declaration of Helsinki and followed the approved protocol.

#### **Consent for publication**

Not applicable.

#### **Competing interests**

The authors declare no competing interests.

#### Received: 5 December 2024 Accepted: 21 April 2025 Published online: 02 May 2025

#### References

- 1. Silveira ER, Cademartori MG, Schuch HS, Armfield JA, Demarco FF. Estimated prevalence of dental fear in adults: A systematic review and meta-analysis. J Dent. 2021;108: 103632.
- Lee C-Y, Chang Y-Y, Huang S-T. Prevalence of dental anxiety among 5- to 8-year-old Taiwanese children. J Public Health Dent. 2007;67(1):36–41.
- Los A, Fiegler-Rudol J, Tysiąc-Miśta M, Tanasiewicz M: Novel nonpharmacological strategies for managing dentophobia in adult patients - literature review. Wiadomosci lekarskie (Warsaw, Poland : 1960) 2024, 77(8):1617–1622.
- Teles FRF, Chandrasekaran G, Martin L, Patel M, Kallan MJ, Furquim C, Hamza T, Cucchiara AJ, Kantarci A, Urquhart O, et al. Salivary and serum inflammatory biomarkers during periodontitis progression and after treatment. J Clin Periodontol. 2024;51(12):1619–31.
- Dongiovanni P, Meroni M, Casati S, Goldoni R, Thomaz DV, Kehr NS, Galimberti D, Del Fabbro M, Tartaglia GM. Salivary biomarkers: novel noninvasive tools to diagnose chronic inflammation. Int J Oral Sci. 2023;15(1):27.
- Papapanou PN, Sanz M, Buduneli N, Dietrich T, Feres M, Fine DH, Flemmig TF, Garcia R, Giannobile WV, Graziani F, et al. Periodontitis: Consensus report of workgroup 2 of the 2017 world workshop on the classification of periodontal and peri-implant diseases and conditions. J Periodontol. 2018;89(Suppl 1):S173-s182.
- Robati M, Ranjbari A, Ghafourian Boroujerdnia M, Chinipardaz Z. Detection of IL-4, IL-6 and IL-12 serum levels in generalized aggressive periodontitis. Iranian journal of immunology : IJI. 2011;8(3):170–5.
- Rathinasamy K, Ulaganathan A, Ramamurthy S, Ganesan R, Saket P, Alamelu S. Estimation of TNF-α Levels in saliva and serum of patients with periodontal health and chronic periodontitis: A case-control study. J Contemp Dent Pract. 2020;21(2):148–51.
- Kaur N, Kaur N, Sarangal V. A study to evaluate the correlation of serum albumin levels with chronic periodontitis. Indian J Dent Res. 2015;26(1):11–4.
- Sheinenzon A, Shehadeh M, Michelis R, Shaoul E, Ronen O. Serum albumin levels and inflammation. Int J Biol Macromol. 2021;184:857–62.
- Ishii K, Venkataiah VS, Kajiwara T, Umezawa K, Suzuki S, Nakano M, Sawaguchi M, Yahata Y, Saito M. Salivary leukocyte esterase activity by SillHa is a risk indicator of periodontal disease. BMC Oral Health. 2023;23(1):187.
- Adibi SS, Hanson R, Fray DF, Abedi T, Neil B, Maher D, Tribble G, Warner BF, Farach-Carson MC. Assessment of oral and overall health parameters using the SillHa Oral Wellness System. Oral Surg Oral Med Oral Pathol Oral Radiol. 2022;133(6):663–74.
- Papapanou PN, Sanz M, Buduneli N, Dietrich T, Feres M, Fine DH, Flemmig TF, Garcia R, Giannobile WV, Graziani F, et al. Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Clin Periodontol. 2018;45(Suppl 20):S162-s170.

- R Core Team: R: A language and environment for statistical computing. R Foundation for Statistical Computing 2023, Vienna, Austria. URL https:// www.R-project.org/.
- Zhu L, Tang Z, Hu R, Gu M, Yang Y. Ageing and inflammation: What happens in periodontium? Bioengineering (Basel, Switzerland). 2023;10(11):1274.
- 16. Wulandari P. The aging process and its relation to periodontal conditions. J Exploration of Immunology. 2023;3(3):207–16.
- Huang Q, Dong X. Prevalence of periodontal disease in middle-aged and elderly patients and its influencing factors. Am J Transl Res. 2022;14(8):5677–84.
- Nomura Y, Tamaki Y, Tanaka T, Arakawa H, Tsurumoto A, Kirimura K, Sato T, Hanada N, Kamoi K. Screening of periodontitis with salivary enzyme tests. J Oral Sci. 2006;48(4):177–83.
- Lang NP, Joss A, Orsanic T, Gusberti FA, Siegrist BE: Bleeding on probing. A predictor for the progression of periodontal disease? Journal of Clinical Periodontology 1986, 13(6):590–596.
- Deng K, Pelekos G, Jin L, Tonetti MS. Gingival bleeding on brushing as a sentinel sign of gingival inflammation: A diagnostic accuracy trial for the discrimination of periodontal health and disease. J Clin Periodontol. 2021;48(12):1537–48.
- Iwasaki M, Usui M, Ariyoshi W, Nakashima K, Nagai-Yoshioka Y, Inoue M, Kobayashi K, Borgnakke WS, Taylor GW, Nishihara T. Validation of a selfreport questionnaire for periodontitis in a Japanese population. Sci Rep. 2021;11(1):15078.
- Ghosh M, Rodriguez-Garcia M, Wira CR. The immune system in menopause: pros and cons of hormone therapy. J Steroid Biochem Mol Biol. 2014;142:171–5.
- 23. Jafri Z, Bhardwaj A, Sawai M, Sultan N. Influence of female sex hormones on periodontium: A case series. J Nat Sci Biol Med. 2015;6(Suppl 1):S146-149.
- Shirmohammadi A, Faramarzi M, Salari A, Sadighi Shamami M, Babaloo AR, Mousavi Z. Effect of non-surgical periodontal treatment on serum albumin levels in patients with chronic periodontitis. J Adv Periodontol Implant Dent. 2018;10(1):18–23.
- Shi D, Meng H, Xu L, Zhang L, Chen Z, Feng X, Lu R, Sun X, Ren X. Systemic inflammation markers in patients with aggressive periodontitis: a pilot study. J Periodontol. 2008;79(12):2340–6.
- Kolte RA, Kolte AP, Kohad RR. Quantitative estimation and correlation of serum albumin levels in clinically healthy subjects and chronic periodontitis patients. J Indian Soc Periodontol. 2010;14(4):227–30.
- 27. Ioannidou E. The sex and gender intersection in chronic periodontitis. Front Public Health. 2017;5:189.
- Gurav A, Jadhav V. Periodontitis and risk of diabetes mellitus. J Diabetes. 2011;3(1):21–8.
- Duarte PM, Felix E, Santos VR, Figueiredo LC, da Silva HDP, Mendes JAV, Feres M, Miranda TS. Patients with type 2 diabetes and severe periodontitis harbor a less pathogenic subgingival biofilm than normoglycemic individuals with severe periodontitis. J Periodontol. 2023;94(10):1210–9.
- Huang LG, Yu CC, Lin MC, Wang YH, Chang YC. Association between periodontitis and hematologic cancer: An NHIRD cohort study in Taiwan. Cancers. 2024;16(9):1671.
- 31. Li X, Chaouhan HS, Li CH, Yu TM, Wang IK, Lin CL, Li CY, Sun KT. Higher risk of gastric helicobacter pylori infection in patients with periodontitis: A nationwide population-based retrospective cohort study in Taiwan. Int J Environ Res Public Health. 2021;18(21):11678.
- Chang KH, Hsu YC, Chiu IM, Chen LC, Hsu CC, Lee CY, Fan HC, Chen HJ, Chou RH. Association between periodontitis and bipolar disorder: A nationwide cohort study. Medicine. 2020;99(31): e21423.
- Deng K, Pelekos G, Jin L, Tonetti MS. Diagnostic accuracy of a point-ofcare aMMP-8 test in the discrimination of periodontal health and disease. J Clin Periodontol. 2021;48(8):1051–65.
- Chew RJJ, Tan KS, Chen T, Al-Hebshi NN, Goh CE. Quantifying periodontitis-associated oral dysbiosis in tongue and saliva microbiomes-An integrated data analysis. J Periodontol. 2025;96(1):55–66.

#### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.